

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/581,294	FIRST NAMED APPLICANT Sudhir Paul	ATTY. DOCKET NO. 7050212001
---	--------------------------------------	--------------------------------

23639
BINGHAM, MCCUTCHEN LLP
THREE EMBARCADERO CENTER
18 FLOOR
SAN FRANCISCO, CA 94111-4067

RECEIVED**OCT 16 2006**

Bingham McCutchen
IP Docket Dept.

INTERNATIONAL APPLICATION NO. PCT/US04/09398	
I.A. FILING DATE 03/26/2004	PRIORITY DATE 03/26/2003

CONFIRMATION NO. 3697**371 FORMALITIES LETTER**

OC000000020642992

Date Mailed: 10/12/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

RW H

Docket: 3004757 705021-2001

Action: Resp- 18he

Date Due: 12/12/2006

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/581,294	PCT/US04/09398	7050212001

FORM PCT/DO/EO/922 (371 Formalities Notice)

NEIFELD IP LAW, P.C.
4813-B Eisenhower Avenue
Alexandria, Virginia 22304

Tel: 703-415-0012
Fax: 703-415-0013
Email: rneifeld@Neifeld.com
Web: www.Neifeld.com



**37 CFR 1.7(c) FILING RECEIPT AND
TRANSMITTAL LETTER WITH
AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT**

Neifeld Docket No.: UTEX0012UPCT-US
US/PCT Application/Patent No.: 10/581,294
Priority Data:
Inventor: Sudhir PAUL
Title: Proteolytic and Covalent Antibodies

Client Ref.:
US/PCT File/Issue Date: 3/26/2004
USPTO Confirmation No.: 3697


**THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON
THE DATE STAMPED HEREON:**

37 CFR 1.7(c) Filing Receipt and Transmittal Letter with Authorization to Charge Deposit Account (in duplicate)
Amendment in Response to Notification to Comply with Requirements for Patent Applications
Containing Nucleotide and/or Amino Acid Sequence Disclosures (3 pages)
Statement Accompanying Sequence Listing
Sequence Listing (5 pages)
Diskette Containing Sequence Listing in Computer-Readable Form
Copy of Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or
Amino Acid Sequence Disclosures Mailed October 12, 2006 (2 pages)

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 50-2106. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

1.12.07
DATE


Robert W. Hahl, Ph.D.
Registration No. 33,893
Attorney of Record

Fees:	PcLaw Matter	Lawyer	Amount	Explanation	Date Entered	Initials
Fees:						
Disbursements:	PcLaw Matter	G/L Account	Amount	Explanation	Date Entered	Initials
		5010				

Printed: September 30, 2005 (1:31pm)

Y:\Info\FirmForms\Firms_Patent\US\Templates-DoNotUse\Combined_37_CFR1_6_FilingReceiptOfCorrespondence_TransmittalLetter.wpd